Arlin Z A, Feldman E, Kempin S, Ahmed T, Mittelman A, Savona S, Ascensao J, Baskind P, Sullivan P, Fuhr H G, Mertelsmann R
Department of Medicine, New York Medical College, Valhalla 10595.
Blood. 1988 Aug;72(2):433-5.
Thirty-six patients with relapsed acute lymphoblastic leukemia (ALL) and four with primary refractory ALL were treated with a regimen that included amsacrine, 200 mg/m2, intravenously daily for three days with cytarabine, 3 gm/m2, by infusion over three hours daily for five days. There were 27 remissions in the 36 relapsed patients and two in the four patients with primary refractory disease. Seventeen of the 23 patients with common ALL, four of the six with T-cell ALL, one of the three with B-cell ALL, and seven of eight whose cells were not characterized responded. Toxicity of this regimen was comparable to other reinduction regimens for ALL, but the side effects characteristic of high-dose cytarabine therapy were absent. Since these results compare favorably with conventional induction regimens, its use in the primary treatment of adults and children with high-risk ALL is proposed.
36例复发急性淋巴细胞白血病（ALL）患者和4例原发性难治性ALL患者接受了一种治疗方案，该方案包括安吖啶，200mg/m²，静脉滴注，每日1次，共3天，同时联合阿糖胞苷，3g/m²，每日静脉滴注3小时，共5天。36例复发患者中有27例缓解，4例原发性难治性疾病患者中有2例缓解。23例普通ALL患者中的17例、6例T细胞ALL患者中的4例、3例B细胞ALL患者中的1例以及8例细胞未分型患者中的7例有反应。该方案的毒性与ALL的其他再诱导方案相当，但没有高剂量阿糖胞苷治疗的典型副作用。由于这些结果与传统诱导方案相比具有优势，因此建议将其用于高危ALL成人和儿童的初始治疗。
